Summary
Propranolol (P) and all of its major known metabolites were found in maternal plasma, cord plasma and neonatal plasma in 10 women at term, irrespective of the P doses administered and the time elapsed (up to 15 h) between administration of the last P dose and delivery. The ratios of cord plasma to simultaneous maternal plasma levels for propranolol and its major metabolites (mean±SD) were: propranolol 0.32±0.17, propranolol glucuronide 0.86±0.36, 4-hydroxypropranolol 1.4±1.0, 4-hydroxypropranolol glucuronide 0.71±0.45 and naphthoxylactic acid 3.0±1.6. P binding in cord plasma at delivery was 67.2±3.9% (mean±SD) which was significantly less (‘t’=13.4,df=13,p<0.001) than the P binding in maternal plasma at delivery (87.5±1.6%, mean±SD). The plasma protein binding (mean±SD) of naphthoxylactic acid in cord plasma (98.6±0.2%) was significantly greater (‘t’=3.808,df=4,p<0.02) than the naphthoxylactic acid binding in maternal plasma at delivery (97.6±0.4%). When the simultaneous concentrations of P and naphthoxylactic acid in maternal and cord plasma are compared in conjunction with protein binding and ionic effects, it would seem that metabolism of P does occur in the placental/foetal unit.
Similar content being viewed by others
References
Cottrill CM, McCallister RG Jr, Gettes L, Noonan JA (1977) Propranolol therapy during pregnancy, labour, and delivery. Evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr 91: 812–814
Goldstein A, Aronow L, Kolman SM (1974) In: Principles of drug action: The basis of pharmacology. Wiley, New York, p 201
Hitzig WH (1963) Die Plasmaproteine in der klinischen Medizin. Springer, Berlin. In: Diem K, Lentner C (eds) Documenta Geigy, Scientific tables (1970). Ciba-Geigy Ltd. (publishers), Basle, Switzerland, p 583
Juchau MR (1976a) Drug biotransformation reactions in the placenta. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 112
Juchau MR (1976b) Drug biotransformation reactions in the placenta. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 114
Juchau MR, Chao ST, Omiecinski CJ (1980) Drug metabolism in the human foetus. Clin Pharmacokinet 5: 320–339
Kosman ME (1973) Current status of propranolol hydrochloride (Inderal). Am J Med Assoc 225: 1380
Levitan AA, Manion JC (1973) Propranolol therapy during pregnancy and lactation. Am J Cardiol 32: 247
Mirkin BL, Singh S (1976) Placental transfer. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 26
Pelkonen O (1980) Environmental influences on human foetal and placental xenobiotic metabolism. Eur J Clin Pharmacol 18: 17–24
Rankin J, Meschia G, Makowski EL, Battaglia FF (1970) Placental transfer. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 17
Smith MT, Livingstone I, Hooper WD, Eadie MJ, Triggs EJ (1983) Propranolol, propranolol glucuronide and naphthoxylactic acid in breast milk and plasma. Ther Drug Monitoring (in press)
Waddell WJ, Marlowe GC (1976) Disposition of drugs in the foetus. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 221
Walle T, Gaffney TE (1972) Propranolol metabolism in man and dog: Mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther 182: 83–92
Wood M, Wood AJJ (1981) Changes in plasma drug binding and α1-acidglycoprotein in mother and newborn infant. Clin Pharmacol Ther 29: 522–526
Yaffe MR, Stern L (1976) Clinical implications of perinatal pharmacology. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 382
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, M.T., Livingstone, I., Eadie, M.J. et al. Metabolism of propranolol in the human maternal-placental-foetal unit. Eur J Clin Pharmacol 24, 727–732 (1983). https://doi.org/10.1007/BF00607078
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607078